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Diagnostic Test: 
PSEUDOCHOLINESTERASE DEFICIENY   
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Pathophysiology 
Cont. 
Drug Effects:  
• Residual anesthetic, including over 








• Hypercarbia  
 
Neurological causes: 
• Increased cerebral hemorrhage 
resulting in increased intracranial 
pressure 
• Ischemic episode  
• Seizure resulting in a post-ictal state 
The most important issue is to keep 
the patient safe and comfortable 
throughout this experience. Always 
remember just because the patient is 
paralyzed does not mean they are not 
aware or pain free. The patient must be 
kept sedated with adequate pain control 
until the prolonged paralysis resolves.  
    Pseudocholinesterase deficiency is a 
rare genetic or acquired variation in the 
metabolism of choline esters such as the 
neuromuscular blockers succinylcholine, 
mivacurium, and ester local anesthetics. 
Pseudocholinesterase deficiency 
genetically is transmitted in an autosomal 
recessive pattern with the frequency of 
apnea from a genetic abnormality of 
pseudocholinesterase between 1:480 and 
1:3200 people (Ok et al., 2013). An 
extended period of neuromuscular 
blockade results from these medications 
than what is clinically expected. The signs 
and symptoms which occur are apnea and 
paralysis hours longer. This condition is 
rare but must be known and understood 
by the clinician in order to provide the 
safest patient care possible. The 
information is not widely known or 
readily available and usually is 
undetected until the patient receives the 
medications and then the neuromuscular 
blockade continues well beyond the 
expected duration. The purpose of this 
discussion is to further educate the 
practitioner on the pathophysiology of 
pseudocholinesterase deficiency, as well 
as signs and symptoms, and patient 
management strategies to improve 
patient outcomes.  




Treatment is aimed at patient safety, 
care and comfort. The standard of care is 
to maintain sedation and ventilation 
until return of normal neuromuscular 
function and patient is able to protect 
their airway. This is considered the 
safest option. The other options are 
transfusions of whole blood and FFP, or 
purified human cholinesterase.  
Treatment 
 Dibucaine is an amide local 
anesthetic that inhibits typical 
pseudocholinesterase. Dibucane is added 
to a sample of the patient’s serum and 
compared to untreated serum to show 
the sensitivity to succinylcholine. A 
Dibucaine number and enzyme activity 
are both determined. A normal result is 
80. The results indicate Dibucaine 
inhibits 80% of pseudocholinesterase 
activity.  A Dibucaine number of 20 is 
diagnostic for atypical 
pseudocholinesterase levels.  
Case Study 
     A 43 year old female is having 
rotator cuff repair s/p rotator cuff tear. 
She has no known drug allergies. Her 
past medical history is GERD and 
hypertension, which she takes 20mg 
lisinopril and 20mg omeprazole. Past 
surgical history is one C-section. Family 
history of anesthetic problems: States 
“thinks her dad may have had difficulty 
waking up but was not sure”. Vitals: 
blood pressure 128/86, heart rate 70, 
SpO2 99% on room air, respirations 16, 
temperature 98.40C. The patient had 
general anesthesia, with standard 
induction consisting of 80mg lidocaine, 
150mg propofol, 5mg rocuronium, and 
140mg succinylcholine. Sevoflurane 2% 
was used for maintenance. Intra-
operative course is uneventful. During 
emergence patient remains apneic, with 
no response to increase in C02. First 
considerations must be differential 
diagnoses for a delayed emergence.  
       After further examination vital signs 
were stable, blood glucose was 108, and 
electrolytes were within normal limits. 
However, train of four was assessed 
resulting in 0/4 twitches, indicating 
prolonged paralysis. This lead to the rare 
conclusion of Pseudocholinesterase 
deficiency. The major signs and 
symptoms occurred postoperatively 
after administration of the muscle 
relaxant succinylcholine for induction 
during surgery. The patient presented 
with apnea, prolonged paralysis, and 
weak or 0/4 twitches with the train of 
four.  
Pathophysiology 
        Pseudocholinesterase is an enzyme 
produced in the liver. The heart, plasma, 
pancreas, and the white matter also 
contain pseudocholinesterase Ama et al. 
(2010). The enzyme is responsible for 
metabolizing succinylcholine, 
mivacurium, and other ester local 
anesthetics such as cocaine and procaine. 
In people with normal 
pseudocholinesterase levels, the 
medications are usually hydrolyzed very 
quickly, even before it reaches the 
neuromuscular junction. According to 
Ama et al. (2010), “this hydrolysis 
rapidly inactivates around 90% to 95% 
of the intravenous succinylcholine dose.  
        
         The remaining 5% to 10% of the 
succinylcholine dose acts as an 
acetylcholine receptor agonist at the 
neuromuscular junction.” This causes 
depolarization of skeletal muscle, which 
results in fasciculations that can be 
seen in the muscles. Once the 
acetylcholine is released from the 
presynaptic membrane, and the 
remainder of the succinylcholine binds 
to the receptors on the postsynaptic 
neuromuscular junction, it is no longer 
able to evoke any more action 
potentials. This is what causes the 
muscle paralysis. The paralysis can 
develop as quickly as one minute. 
Elimination of succinylcholine is 
accomplished by pseudocholinesterase 
enzyme diffusing the medication away 
from the acetylcholine receptors. It is 
first metabolized into 
succinylmonocholine, which is 1/20th 
to 1/90th as potent as succinylcholine 
and then broken down to succinate and 
choline  Ama et al. (2010). Normally, a 
patient recovers fully from 
succinylcholine (0.5-1.0 mg/kg) within 
5 minutes. However, a patient who has 
pseudocholinesterase deficiency is 
unable to metabolize the medication as 
quickly as a person with normal levels. 
This leads to increased number of 
succinylcholine molecules in the 
neuromuscular junction, causing the 
duration of paralytic effect to continue 
for up to 8 hours.  
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Pseudocholinesterase deficiency is a 
rare cause of prolonged paralysis. The 
potential risk of this deficiency can be 
life threatening, thus indicating the 
importance of education about this 
topic. A thorough preoperative 
evaluation is crucial including a detailed 
family history and always further 
assessing a patient who states a family 
history or personal history of difficulty 
waking up after surgery. The clinician 
must be aware of the most recognizable 
symptom, which is prolonged apnea 
after surgery with administration of the 
neuromuscular blocker succinylcholine.  
Dibucaine 
Inhibition Test 
Results 
  
Nursing Implications 
